ONC Stock Summary and Trading Ideas (Beone Medicines Ltd. - American Depositary Shares | NASDAQ:ONC)

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.

As of February 12, 2026, ONC stock price declined to $346.42 with 128,288 million shares trading.

ONC has a beta of 0.43, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.03 to the broad based SPY ETF.

ONC has a market cap of $38.33 billion. This is considered a Large Cap stock.

Last quarter Beone Medicines Ltd. - American Depositary Shares reported $1 billion in Revenue and $2.65 earnings per share. This beat revenue expectation by $58 million and exceeded earnings estimates by $1.85.

The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, BBH, CGIE.

ONC has outperformed the market in the last year with a price return of +56.6% while the SPY ETF gained +13.8%. ONC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +0.8% and -1.0%, respectively, while the SPY returned 0.0% and -2.0%, respectively.

ONC support price is $343.20 and resistance is $359.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.